Summarized by Masters of Longevity from Longevity Technology.
A short feature explaining a funded team’s plan to use pilot mitochondrial drug data to design a larger trial aimed at improving aging outcomes.
Key Takeaways
- Mighty Therapeutics and the University of Washington received a $1 million Milestone 2 award from XPRIZE Healthspan.
- The award is based on pilot data of elamipretide that will inform a larger randomized placebo-controlled trial in older adults.
- Final XPRIZE winners will be selected by 2030 after rigorous trials measuring muscle, cognitive, and immune function improvements.
